REVVITY, INC., 10-Q filed on 5/12/2026
Quarterly Report
v3.26.1
Cover Page - shares
 3 Months Ended
Apr. 05, 2026
May 08, 2026
Entity Listings [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Apr. 05, 2026  
Document Transition Report false  
Entity File Number 001-5075  
Entity Registrant Name REVVITY, INC  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 04-2052042  
Entity Address, Address Line One 77 4th Avenue,  
Entity Address, City or Town Waltham,  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02451  
City Area Code 781  
Local Phone Number 663-6900  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   111,559,773
Entity Central Index Key 0000031791  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Current Fiscal Year End Date --01-03  
RVTY [Member]    
Entity Listings [Line Items]    
Trading Symbol RVTY  
Trading Symbol RVTY  
RVTY 21A [Member]    
Entity Listings [Line Items]    
Trading Symbol RVTY 26  
Trading Symbol RVTY 26  
Common stock, $1 par value per share [Member]    
Entity Listings [Line Items]    
Title of 12(b) Security Common stock, $1 par value per share  
Title of 12(b) Security Common stock, $1 par value per share  
1.875% Notes due 2026 [Member]    
Entity Listings [Line Items]    
Title of 12(b) Security 1.875% Notes due 2026  
Title of 12(b) Security 1.875% Notes due 2026  
NEW YORK STOCK EXCHANGE, INC. [Member]    
Entity Listings [Line Items]    
Security Exchange Name NYSE  
Security Exchange Name NYSE  
v3.26.1
Condensed Consolidated Income Statements - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Segment revenue $ 711,118 $ 664,762
Cost of Product and Service Sold 323,463 289,216
Selling, general and administrative expenses 253,882 249,719
Research and development expenses 57,887 53,597
Operating income from continuing operations 75,886 72,230
Interest And Other Expense Net 25,894 19,848
Income from continuing operations before income taxes 49,992 52,382
Provision for income taxes 9,099 10,713
Income from continuing operations 40,893 41,669
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest (175) 568
Net income $ 40,718 $ 42,237
Basic earnings (loss) per share:    
Income (loss) from continuing operations (per share) $ 0.37 $ 0.35
Gain (loss) on discontinued operations and dispositions (per share) 0.00 0.00
Net income (per share) 0.36 0.35
Diluted earnings (loss) per share:    
Income (loss) from continuing operations (per share) 0.37 0.35
Gain (loss) on discontinued operations and dispositions (per share) 0.00 0.00
Net income (per share) $ 0.36 $ 0.35
Weighted average shares of common stock outstanding:    
Basic (in shares) 111,852 120,137
Diluted (in shares) 111,876 120,233
Product [Member]    
Segment revenue $ 581,458 $ 562,680
Cost of Product and Service Sold 273,320 250,155
Service [Member]    
Segment revenue 129,660 102,082
Cost of Product and Service Sold $ 50,143 $ 39,061
v3.26.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock Amount [Member]
Common Stock Amount [Member]
Net Income [Member]
Common Stock Amount [Member]
Other comprehensive loss [Member]
Common Stock Amount [Member]
Dividends [Member]
Common Stock Amount [Member]
Exercise of employee stock options and related income tax benefits [Member]
Common Stock Amount [Member]
Purchases of common stock [Member]
Common Stock Amount [Member]
Issuance of common stock for employee stock purchase plans [Member]
Common Stock Amount [Member]
Issuance of common stock for long-term incentive program [Member]
Common Stock Amount [Member]
Stock compensation [Member]
Capital In Excess of Par Value [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Common stock, Shares, Issued and outstanding   (120,646,000)                      
Beginning Balance at Dec. 29, 2024 $ 7,666,874 $ 120,646                 $ 2,097,110 $ 5,845,223 $ (396,105)
Net income 42,237                     42,237  
Other comprehensive income (loss) 79,654                        
Dividends (8,243)                     (8,243)  
Exercise of employee stock options and related income tax benefits 2,632 32                 2,600    
Issuance of common stock for employee benefit plans (1,272) (12)                 (1,260) 0 0
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations (154,987) (1,356)                 (153,631)    
Issuance of common stock for long-term incentive program (5,599) (75)                 (5,524)    
Stock compensation 2,092 0                 2,092 0 0
Ending Balance at Mar. 30, 2025 7,637,130 $ 119,409                 1,954,955 5,879,217 (316,451)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax $ 79,654                       79,654
Common stock, Shares, Issued and outstanding   (119,409,000) 0 0 0 (32,000) (1,356,000) (12,000) (75,000) 0      
Common stock, Shares, Issued and outstanding (112,281,000) (112,281,000)                      
Beginning Balance at Dec. 28, 2025 $ 7,250,360 $ 112,281                 1,305,900 6,054,314 (222,135)
Net income 40,718                     40,718  
Other comprehensive income (loss) (31,421)                        
Dividends (7,810)                     (7,810)  
Exercise of employee stock options and related income tax benefits 5,441 60                 5,381    
Issuance of common stock for employee benefit plans (1,229) (13)                 (1,216)    
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations (84,537) (837)                 (83,700)    
Issuance of common stock for long-term incentive program (5,870) (112)                 (5,758)    
Stock compensation 2,889 0                 2,889 0 0
Ending Balance at Apr. 05, 2026 7,182,739 $ 111,629                 $ 1,237,444 $ 6,087,222 (253,556)
Other Comprehensive Income (Loss), after Reclassifications, Net of Tax $ (31,421)                       $ (31,421)
Common stock, Shares, Issued and outstanding (111,629,000) (111,629,000) 0 0 0 (60,000) (837,000) (13,000) (112,000) 0      
v3.26.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Net income $ 40,718 $ 42,237
Other Comprehensive Income (Loss), Net of Tax [Abstract]    
Foreign currency translation adjustments, net of income taxes, recognized in other comprehensive income (32,492) 79,654
Unrecognized prior service credits, net of income taxes 798 0
Unrealized gain on securities, net of income taxes 273 0
Other comprehensive (loss) income (31,421) 79,654
Comprehensive income $ 9,297 $ 121,891
v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Apr. 05, 2026
Dec. 28, 2025
Current assets:    
Cash and cash equivalents $ 860,320 $ 919,860
Accounts receivable, net 691,380 744,671
Inventories, net 387,505 379,497
Other current assets 189,112 195,719
Total current assets 2,128,317 2,239,747
Property, plant and equipment, net:    
Property, plant and equipment, net 465,636 479,249
Operating Lease, Right-of-Use Asset 163,254 165,439
Intangible assets, net 2,306,534 2,347,003
Goodwill 6,610,750 6,613,493
Other assets, net 322,099 323,480
Total assets 11,996,590 12,168,411
Current liabilities:    
Current portion of long-term debt 575,831 588,828
Accounts payable 169,679 185,464
Accrued expenses and other current liabilities 493,134 556,954
Total current liabilities 1,238,644 1,331,246
Long-term debt 2,632,072 2,631,236
Deferred taxes and other long-term liabilities 800,859 807,461
Operating Lease, Liability, Noncurrent 142,276 148,108
Total liabilities 4,813,851 4,918,051
Commitments and contingencies (see Note 14)
Stockholders' equity:    
Preferred stock—$1 par value per share, authorized 1,000,000 shares; none issued or outstanding 0 0
Common stock—$1 par value per share, authorized 300,000,000 shares; issued and outstanding 111,629,000 shares and 112,281,000 shares at April 5, 2026 and December 28, 2025, respectively 111,629 112,281
Capital in excess of par value 1,237,444 1,305,900
Retained earnings 6,087,222 6,054,314
Accumulated other comprehensive loss (253,556) (222,135)
Total stockholders’ equity 7,182,739 7,250,360
Total liabilities and stockholders’ equity $ 11,996,590 $ 12,168,411
v3.26.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Apr. 05, 2026
Dec. 28, 2025
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 1 $ 1
Preferred stock, authorized 1,000,000 1,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value $ 1 $ 1
Common stock, authorized 300,000,000 300,000,000
Common stock, issued 111,629,000 112,281,000
Common stock, Shares, Issued and outstanding 111,629,000 112,281,000
v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Operating activities:    
Net income $ 40,718 $ 42,237
Loss (income) from discontinued operations, net of income taxes 175 (568)
Income from continuing operations 40,893 41,669
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:    
Restructuring and other costs 10,675 3,239
Depreciation and amortization 105,056 97,422
Gain on disposition of businesses and assets, net (5,074) 0
Stock-based compensation 8,715 7,731
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) (99) (625)
Amortization of deferred debt financing costs and accretion of discounts 1,139 1,102
Change in fair value of financial securities 4,204 (3,073)
Unrealized Foreign Exchange (Gain) Loss Related to Proceed from Sale of Business 100 (66)
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:    
Accounts receivable, net 61,547 18,140
Inventories (12,838) (5,486)
Accounts payable (13,744) 8,854
Increase (Decrease) in Accrued Expenses and Other (74,687) (34,810)
Net cash provided by operating activities of continuing operations 125,887 134,097
Net cash used in operating activities of discontinued operations (10,657) (5,942)
Net cash provided by operating activities 115,230 128,155
Investing activities:    
Capital expenditures (19,775) (15,982)
Purchases of investments and notes receivables (1,055) 0
Proceeds from investments and notes receivables 677 0
Proceeds from disposition of property, plant and equipment 9,003 0
Proceeds from disposition of businesses and assets 158 229
Cash paid for acquisitions, net of cash acquired (67,280) 0
Net cash used in investing activities of continuing operations (78,272) (15,753)
Net cash provided by investing activities of discontinued operations 0 9,375
Net cash used in investing activities (78,272) (6,378)
Financing activities:    
Payments of debt financing issuance costs 0 (2,402)
Net payments on other credit facilities 0 (50)
Payment for Contingent Consideration Liability, Financing Activities 0 (1,817)
Proceeds from issuance of common stock under stock plans 5,441 2,632
Purchases of common stock (86,496) (153,594)
Dividends paid (7,840) (8,433)
Net cash used in financing activities (88,895) (163,664)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (7,627) 16,122
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalent (59,564) (25,765)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at beginning of period 921,030 1,164,452
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at end of period 861,466 1,138,687
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]    
Cash and cash equivalents 860,320 1,137,620
Restricted Cash, Current 428 1,067
Restricted Cash, Noncurrent 718 0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 861,466 $ 1,138,687
v3.26.1
Basis of Presentation
 3 Months Ended
Apr. 05, 2026
Accounting Policies [Abstract]  
Basis of Accounting [Text Block] Basis of Presentation
The condensed consolidated financial statements included herein have been prepared by Revvity, Inc. (the “Company”), in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the “United States”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 28, 2025, filed with the SEC (the “2025 Form 10-K”). The balance sheet amounts at December 28, 2025 in this report were derived from the Company’s audited 2025 consolidated financial statements included in the 2025 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended April 5, 2026 and March 30, 2025, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period.
The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending January 3, 2027 (“fiscal year 2026”) will include 53 weeks, and the fiscal year ended December 28, 2025 (“fiscal year 2025”) included 52 weeks.
Accounting Standards Not Yet Adopted: In December 2025, the FASB issued Accounting Standards Update 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities (“ASU 2025-10”), which establishes authoritative guidance on the recognition, measurement, presentation, and disclosure of government grants. Under ASU 2025-10, government grants are recognized when it is probable that the entity will both comply with the conditions of the grant and the grant will be received. ASU 2025-10 provides specific accounting models for grants related to assets and grants related to income, including options to recognize government grants as deferred income or as a reduction of the asset’s cost basis. ASU 2025-10 also requires enhanced disclosures regarding the nature of government grants, significant terms and conditions, accounting policies applied, and amounts recognized in the financial statements. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-10 but does not expect the impact of such adoption to be material.
In December 2025, the FASB issued Accounting Standards Update 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements (“ASU 2025-11”), which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. ASU 2025-11 provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-11.
In September 2025, the FASB issued Accounting Standards Update 2025-06, Targeted Improvements to the Accounting for Internal-Use Software (“ASU 2025-06”). ASU 2025-06 amends certain aspects of the accounting for and disclosure of software costs. The amendments in this update are effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The guidance may be applied prospectively, retrospectively, or via a modified prospective transition method. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures.
In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 will require public entities to disclose disaggregated information about specific natural expense categories underlying certain income statement expense line items. Such disclosures are required on an annual and interim basis in a tabular presentation in the footnotes to the financial statements. In addition, ASU 2024-03 requires public entities to disclose selling expenses on an annual and interim basis. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is in the process of determining the impact of this guidance on its financial statements and disclosures. This accounting standard will increase disclosures in the Company’s annual and interim reporting when adopted.
v3.26.1
Revenue (Notes) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Disaggregation of Revenue [Line Items]    
Revenue from Contract with Customer [Text Block] Revenue
Disaggregation of revenue
Disaggregated revenue by primary geographical markets and major goods and service lines are as follows:
Reportable Segments
Three Months Ended
April 5, 2026March 30, 2025
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$185,551 $130,441 $315,992 $184,279 $120,350 $304,629 
Europe91,695 131,351 223,046 76,022 105,770 181,792 
Asia84,599 87,481 172,080 80,094 98,247 178,341 
$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 
Major goods/service lines
Life Sciences Solutions$299,996 $— $299,996 $286,453 $— $286,453 
Software61,849 — 61,849 53,942 — 53,942 
Immunodiagnostics— 201,831 201,831 — 197,562 197,562 
Reproductive Health— 147,442 147,442 — 126,805 126,805 
$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 

Contract Balances
Unbilled receivable and Contract assets: The timing of revenue recognition may differ from the timing of customer billing. When revenue is recognized prior to billing and the right to the amount due from customers is conditioned only on the passage of time, the Company records an unbilled receivable on its consolidated balance sheets. Unbilled receivables totaled $106.7 million at April 5, 2026, of which $74.4 million was included in “Accounts receivable, net” and $32.3 million was included in “Other assets, net” in the condensed consolidated balance sheet. Unbilled receivables totaled $105.6 million at December 28, 2025, of which $72.4 million was included in “Accounts receivable, net” and $33.2 million was included in “Other assets, net” in the condensed consolidated balance sheet. Unbilled receivables primarily related to software revenue.The Company had no material contract assets as of April 5, 2026 and December 28, 2025.
Deferred revenue and Customer deposits: Deferred revenue is recorded when revenue is recognized subsequent to customer invoicing. Deferred revenue is classified as either current in “Accrued expenses and other current liabilities” or as long-term in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The deferred revenue balance is primarily related to the Company’s software as a service offerings, maintenance contracts and prepaid storage arrangements. Deferred revenue totaled $238.5 million at April 5, 2026, of which $171.7 million was included in “Accrued expenses and other current liabilities” and $66.8 million was included in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheet. Deferred revenue totaled $224.8 million at December 28, 2025, of which $159.3 million was included in “Accrued expenses and other current liabilities” and $65.5 million was included in “Deferred taxes and other long-term liabilities” in the condensed consolidated balance sheet. The Company also had customer deposits received in advance of the transfer of control totaling $20.3 million and $19.3 million at April 5, 2026 and December 28, 2025, respectively, which was included in “Accrued expenses and other current liabilities” in the condensed consolidated balance sheet. The Company expects that these customer deposits will be recognized in revenue within three months of the balance sheet date.
Transaction price allocated to the remaining performance obligations
The Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
  
Segment revenue $ 711,118 $ 664,762
Americas [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 315,992 304,629
Europe [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 223,046 181,792
Asia [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 172,080 178,341
Life Sciences Solutions [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 299,996 286,453
Software [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 61,849 53,942
Reproductive health [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 147,442 126,805
Applied genomics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue   664,762
Immunodiagnostics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 201,831 197,562
Diagnostics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 349,273 324,367
Diagnostics [Member] | Americas [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 130,441 120,350
Diagnostics [Member] | Europe [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 131,351 105,770
Diagnostics [Member] | Asia [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 87,481 98,247
Diagnostics [Member] | Life Sciences Solutions [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 0 0
Diagnostics [Member] | Software [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 0 0
Diagnostics [Member] | Reproductive health [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 147,442 126,805
Diagnostics [Member] | Immunodiagnostics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 201,831 197,562
Life Sciences [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 361,845 340,395
Life Sciences [Member] | Americas [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 185,551 184,279
Life Sciences [Member] | Europe [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 91,695 76,022
Life Sciences [Member] | Asia [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 84,599 80,094
Life Sciences [Member] | Life Sciences Solutions [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 299,996 286,453
Life Sciences [Member] | Software [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 61,849 53,942
Life Sciences [Member] | Reproductive health [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue 0 0
Life Sciences [Member] | Immunodiagnostics [Member]    
Disaggregation of Revenue [Line Items]    
Segment revenue $ 0 $ 0
v3.26.1
Business Combinations
 3 Months Ended
Apr. 05, 2026
Business Combination [Abstract]  
Business Combinations Business Combinations
Acquisitions in fiscal year 2026
During the first quarter of fiscal year 2026, the Company completed its acquisition of Advanced Chemistry Development Inc. (“ACD/Labs”) for $72.0 million in cash paid at closing and up to $8.0 million in contingent consideration to be paid in cash based on the achievement of certain revenue metrics through 2028. ACD/Labs is based in Toronto, Canada, has approximately 200 employees, and is a provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. The Company has reported the operations for this acquisition within the results of the Company’s Life Sciences segment from the acquisition date. Identifiable definite-lived intangible assets, such as developed technology ($30.1 million), trade names and trademarks ($0.8 million), customer relationships ($18.2 million) and backlog ($1.1 million), acquired as part of this acquisition had a weighted-average amortization period of 11.3 years. The Company recorded $32.0 million of goodwill in the period.
v3.26.1
Restructuring and Related Activities
 3 Months Ended
Apr. 05, 2026
Restructuring and Related Activities [Abstract]  
Restructuring and Other Costs Restructuring and Other Costs
Restructuring and other costs in the first quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.
In the first quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the Company’s workforce.
Restructuring and other costs in the first quarter of fiscal year 2025 primarily consisted of charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.
Restructuring and other costs, which are included in the selling, general and administrative expenses in the consolidated statements of operations, by segment were as follows:
 
Three Months Ended
April 5,
2026		March 30,
2025
 (In thousands)
Life Sciences$3,229 $2,528 
Diagnostics7,554 135 
Corporate(108)576 
$10,675 $3,239 
The following table summarizes the changes in the Company’s accrued restructuring balance for the first quarter of fiscal year 2026. Other amounts reported as restructuring and other costs during the three months ended April 5, 2026 in the accompanying statement of income have been summarized in the notes to the table. Remaining obligations related to these accounts are expected to be paid over the next 12 months and are included in accrued expenses and other current liabilities in the consolidated balance sheets.
(In thousands)
Balance at December 28, 2025$17,793 
Net restructuring charges incurred in 2026 (a)
7,746 
Payments(11,555)
Balance at April 5, 2026$13,984 
(a) Excludes $2.9 million of charges, principally $1.2 million of lease abandonment charges and $0.4 million of acceleration of depreciation of fixed assets and other charges in the Diagnostics segment and $1.3 million of lease abandonment charges in the Life Sciences segment.
v3.26.1
Interest and Other Expense (Income), Net
 3 Months Ended
Apr. 05, 2026
Other Income and Expenses [Abstract]  
Interest and Other Expense (Income), Net Interest and Other Expense, Net
Interest and other expense, net, consisted of the following:
 Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Interest income$(6,304)$(10,081)
Interest expense24,718 22,964 
Change in fair value of investments4,204 (3,073)
Other components of net periodic pension (credit) cost(251)6,787 
Foreign exchange losses and other expense, net3,527 3,251 
Total interest and other expense, net$25,894 $19,848 
v3.26.1
Inventories, Net
 3 Months Ended
Apr. 05, 2026
Inventory Disclosure [Abstract]  
Inventories, Net Inventories, net
Inventories, net consisted of the following:
April 5,
2026		December 28,
2025
 (In thousands)
Raw materials$169,780 $173,033 
Work in progress71,466 68,983 
Finished goods146,259 137,481 
Total inventories, net$387,505 $379,497 
v3.26.1
Debt
 3 Months Ended
Apr. 05, 2026
Debt Disclosure [Abstract]  
Debt Debt
The Company’s debt consisted of the following:

April 5, 2026
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(2,677)$(2,677)
1.900% Senior Unsecured Notes due in 2028
500,000 (135)(1,634)498,231 
3.3% Senior Unsecured Notes due in 2029
850,000 (1,101)(3,048)845,851 
2.55% Senior Unsecured Notes due in March 2031400,000 (71)(1,871)398,058 
2.250% Senior Unsecured Notes due in September 2031
500,000 (883)(2,537)496,580 
3.625% Senior Unsecured Notes due in 2051
400,000 (3)(3,968)396,029 
   Total Long-Term Debt2,650,000 (2,193)(15,735)2,632,072 
Current Portion of Long-term Debt:
€500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”)
576,150 (174)(145)575,831 
   Total$3,226,150 $(2,367)$(15,880)$3,207,903 
On January 7, 2025, the Company entered into a senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.5 billion available through January 7, 2030. Borrowings will bear interest, payable quarterly or, if earlier, at the end of any interest period, at the Company’s option at either (a) the base rate (as described in the credit agreement), or (b) the Term Secured Overnight Financing Rate (“Term SOFR”) (as described in the credit agreement), in each case plus a percentage spread based on the credit rating of the Company’s debt. The base rate is the highest of (a) the Federal Funds Rate (as defined in the credit agreement) plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate”, and (c) Term SOFR plus 1.00%. The credit agreement for the new facility contains customary affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capitalization ratio that remains applicable for so long as the Company’s debt is rated as investment grade. In the event that the Company’s debt is not rated as investment grade, the debt-to-capitalization ratio covenant is replaced with leverage ratio and interest coverage ratio covenants.
v3.26.1
Earnings Per Share
 3 Months Ended
Apr. 05, 2026
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations:
 Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Number of common shares—basic111,852 120,137 
Effect of dilutive securities:
Stock options10 42 
Restricted stock awards14 54 
Number of common shares—diluted111,876 120,233 
Number of potentially dilutive securities excluded from calculation due to antidilutive impact1,455 1,134 
Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.
v3.26.1
Industry Segment Information
 3 Months Ended
Apr. 05, 2026
Segment Reporting [Abstract]  
Industry Segment Information Segment Information
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer (“CEO”). The CEO evaluates the performance of the Company’s operating segments based on revenue and operating income as adjusted for certain items. Intersegment revenue and transfers are not significant. The accounting policies of the operating segments are the same as those described in Note 1, Nature of Operations and Accounting Policies, to the audited consolidated financial statements in the 2025 Form 10-K.
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
The primary financial measure by which the CODM evaluates the performance of Company’s segments is adjusted operating income. Adjusted operating income consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, primarily including restructuring actions, significant litigation matters and transformation costs. The CODM does not evaluate operating segments using discrete asset information and segment assets are not reported to the CODM. Accordingly, no segment assets have been reported.
Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below:  
April 5, 2026March 30, 2025
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 
Segment cost of revenue131,574 156,753 119,321 135,190 
Segment selling, general and administrative expenses94,668 90,192 87,094 89,891 
Segment research and development expenses31,624 26,206 28,269 25,271 
Segment operating income$103,979 $76,122 180,101 $105,711 $74,015 179,726 
Corporate expenses(12,247)(9,815)
Amortization of intangible assets(85,081)(82,700)
Purchase accounting adjustments(141)177 
Acquisition and divestiture-related costs(282)(2,541)
Disposition of businesses and assets, net5,074 — 
Transformation costs(794)— 
Significant litigation matters and settlements(69)(10,586)
Significant environmental matters— 1,208 
Restructuring and other(10,675)(3,239)
Interest and other expense, net(25,894)(19,848)
Income from continuing operations before income taxes$49,992 $52,382 
Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Life Sciences$9,905 $7,185 
Diagnostics9,560 6,846 
Corporate510 691 
Total depreciation expense$19,975 $14,722 
v3.26.1
Stockholders' Equity
 3 Months Ended
Apr. 05, 2026
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Comprehensive Income:
The components of accumulated other comprehensive loss consisted of the following:
April 5,
2026		December 28,
2025
 (In thousands)
Foreign currency translation adjustments, net of income taxes$(253,554)$(221,062)
Unrecognized prior service costs, net of income taxes— (798)
Unrealized net losses on marketable securities, net of income taxes(2)(275)
Accumulated other comprehensive loss$(253,556)$(222,135)
The unrealized foreign exchange losses (gains), net of income taxes, on intercompany debt for which repayment is not anticipated in the foreseeable future that was recorded in accumulated other comprehensive income (“AOCI”) were $39.9 million and $(58.1) million for the three months ended April 5, 2026 and March 30, 2025, respectively.
Income tax (benefit) expense related to foreign currency translation adjustments recognized in AOCI was $(12.9) million for the three months ended April 5, 2026 and $4.2 million for the three months ended March 30, 2025.
Stock Repurchases:
On October 23, 2025, the Company’s Board of Directors (the “Board”) authorized the Company to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). The Repurchase Program will expire on October 22, 2027 unless terminated earlier by the Board and may be suspended or discontinued at any time. During the three months ended April 5, 2026, the Company repurchased 784,142 shares of common stock under the Repurchase Program for an aggregate cost of $79.0 million. As of April 5, 2026, $800.5 million remained available for aggregate repurchases of shares under the Repurchase Program.
Subsequent to the first quarter of fiscal year 2026, the Company repurchased 93,303 shares of common stock under the Repurchase Program at an aggregate cost of $7.8 million.
In addition, the Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company’s equity incentive plans. During the three months ended April 5, 2026, the Company repurchased 51,115 shares of common stock for this purpose at an aggregate cost of $5.0 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.
Dividends:
The Board declared a regular quarterly cash dividend of $0.07 per share for the first quarter of fiscal year 2026 and in each quarter of fiscal year 2025. At April 5, 2026, the Company had accrued $7.8 million for dividends declared on January 26, 2026 for the first quarter of fiscal year 2026 that were paid in May 2026. On April 30, 2026, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the second quarter of fiscal year 2026 that will be payable in August 2026. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.
v3.26.1
Goodwill and Intangible Assets, Net
 3 Months Ended
Apr. 05, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
The Company tests goodwill at least annually for possible impairment. The Company completes the annual testing of impairment for goodwill on the later of November 1 or the first day of its eleventh fiscal month of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill.
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. If the carrying value of the reporting unit exceeds its fair value, an impairment loss in an amount equal to that excess is recognized up to the amount of goodwill.
The changes in the carrying amount of goodwill for the three months ended April 5, 2026 were as follows:
Life SciencesDiagnosticsConsolidated
 (In thousands)
Balance at December 28, 2025$4,744,962 $1,868,531 $6,613,493 
Foreign currency translation(24,952)(9,826)(34,778)
Acquisitions32,035 — 32,035 
Balance at April 5, 2026$4,752,045 $1,858,705 $6,610,750 
Identifiable intangible asset balances by category were as follows:
April 5,
2026		December 28,
2025
 (In thousands)
Patents$27,592 $27,592 
Less: Accumulated amortization(26,579)(26,524)
Net patents1,013 1,068 
Trade names and trademarks148,996 150,103 
Less: Accumulated amortization(103,298)(102,234)
Net trade names and trademarks45,698 47,869 
Licenses27,550 27,561 
Less: Accumulated amortization(20,214)(19,849)
Net licenses7,336 7,712 
Core technology1,641,071 1,624,925 
Less: Accumulated amortization(945,967)(921,325)
Net core technology695,104 703,600 
Customer relationships2,886,388 2,870,384 
Less: Accumulated amortization(1,329,005)(1,283,630)
Net customer relationships1,557,383 1,586,754 
Total$2,306,534 $2,347,003 
Total amortization expense related to amortizable intangible assets was $85.1 million and $82.7 million for the three months ended April 5, 2026 and March 30, 2025, respectively. Estimated amortization expense related to amortizable intangible assets is $254.5 million for the remainder of fiscal year 2026, $312.7 million for fiscal year 2027, $286.8 million for fiscal year 2028, $256.7 million for fiscal year 2029, and $227.9 million for fiscal year 2030
v3.26.1
Derivatives And Hedging Activities
 3 Months Ended
Apr. 05, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives and Hedging Activities Derivatives and Hedging Activities
The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. As a result, fluctuations in foreign currency exchange rates can increase the costs of financing, investing and operating the business.
In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s condensed consolidated statement of cash flows.
Principal hedged currencies include the Chinese Renminbi, British Pound, Euro and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $459.8 million and $598.4 million at April 5, 2026 and December 28, 2025, respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of the three months ended April 5, 2026 and March 30, 2025.
During fiscal year 2018, the Company designated a portion of the 2026 Notes to hedge its net investments in certain foreign subsidiaries. Unrealized translation adjustments from a portion of the 2026 Notes were included in the foreign currency translation component of AOCI, which offsets translation adjustments on the underlying net assets of foreign subsidiaries. The cumulative translation gains or losses will remain in AOCI until the foreign subsidiaries are liquidated or sold. As of April 5, 2026, the total notional amount of the 2026 Notes that was designated to hedge net investments in foreign subsidiaries was €498.6 million. The unrealized foreign exchange (gains) losses recorded in AOCI related to the net investment hedge were $(13.3) million and $19.2 million for the three months ended April 5, 2026 and March 30, 2025, respectively.
The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive loss into interest and other expense, net within the next twelve months.
v3.26.1
Fair Value Measurements
 3 Months Ended
Apr. 05, 2026
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities, accounts receivable and notes receivable. The Company believes it had no significant concentrations of credit risk as of April 5, 2026.
The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the three months ended April 5, 2026. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition and divestiture related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of April 5, 2026 and December 28, 2025 classified in one of the three classifications described above:
 Fair Value Measurements at April 5, 2026 Using:
 Total Carrying Value at April 5, 2026Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$22,865 $22,865 $— $— 
Foreign exchange derivative assets585 — 585 — 
Foreign exchange derivative liabilities(381)— (381)— 
Contingent consideration asset14,890 — — 14,890 
Contingent consideration liabilities(25,011)— — (25,011)
 
 Fair Value Measurements at December 28, 2025 Using:
 Total Carrying Value at December 28, 2025Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$27,956 $27,956 $— $— 
Foreign exchange derivative assets1,832 — 1,832 — 
Foreign exchange derivative liabilities(1,487)— (1,487)— 
Contingent consideration asset14,890 — — 14,890 
Contingent consideration liabilities(17,869)— — (17,869)
Level 1 and Level 2 Valuation Techniques:    The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.
Marketable securities - available for sale: Includes equity and mutual fund investments measured at fair value using the quoted market prices in active markets at the reporting date.
Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company’s condensed consolidated balance sheet on a net basis and are recorded in other assets. As of both April 5, 2026 and December 28, 2025, none of the master netting arrangements involved collateral.
Level 3 Valuation Techniques: The Company’s Level 3 assets and liabilities are comprised of contingent consideration related to the sale of certain assets and the equity interests constituting the Company’s Applied, Food and Enterprise Services business (the “Business”) during fiscal year 2023 and acquisitions. For assets and liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 assets and liabilities.

Contingent consideration:    Contingent consideration is measured at fair value at the disposition or acquisition date using projected milestone dates, discount rates, volatility, probabilities of success and projected achievement of financial targets, including revenues of the acquired business in many instances. Projected risk-adjusted contingent payments are discounted back to the current period using a discounted cash flow model.
The fair value of the contingent consideration asset was initially measured using a lattice model and recognized upon the sale of the Business on March 13, 2023. In accordance with the terms of the sale of the Business, the Company is entitled to receive up to $150.0 million that is contingent on the exit valuation the buyer and its affiliated funds receive on a sale or other capital event related to the Business. Potential valuation adjustments may be made as additional information and market factors that impact the expected exit valuation of the Business becomes available, with the impact of such adjustments being recorded in the Company’s condensed consolidated statements of operations. Adjustments to the fair value since initial recognition were not material. As of April 5, 2026 and December 28, 2025, the carrying value of the contingent consideration asset was $14.9 million.

The fair values of contingent consideration liabilities are calculated on a quarterly basis based on a collaborative effort of the Company’s operations, finance and accounting groups, as appropriate. Valuation adjustments are made as additional information becomes available, including the progress towards achieving the revenue targets, with the impact of such adjustments being recorded in the Company’s condensed consolidated statements of operations.
A reconciliation of the beginning and ending Level 3 contingent consideration liabilities is as follows:
 Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Balance at beginning of period$(17,869)$(21,753)
Additions(8,000)— 
Amounts paid and foreign currency translation759 1,388 
Change in fair value (included within selling, general and administrative expenses)99 625 
Balance at end of period$(25,011)$(19,740)
Financial Instruments Not Recorded at Fair Value
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
The Company’s outstanding senior unsecured notes had an aggregate fair value of $2,950.6 million and an aggregate carrying value of $3,210.6 million as of April 5, 2026. The Company’s outstanding senior unsecured notes had an aggregate fair value of $2,963.7 million and an aggregate carrying value of $3,222.9 million as of December 28, 2025. The fair values of the outstanding senior unsecured notes were estimated using market quotes from brokers and were based on current rates offered for similar debt, which are Level 2 measurements.
v3.26.1
Contingencies
 3 Months Ended
Apr. 05, 2026
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $10.7 million and $10.8 million as of April 5, 2026 and December 28, 2025, respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters and does not include any potential liability for related personal injury or property damage claims. These amounts were included in accrued expenses and other current liabilities. The Company’s environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities, including product liability claims. Legal defense costs are recognized as incurred, and insurance recoveries are recognized when collection is probable. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at the reporting date, the total cost of resolving these contingencies at April 5, 2026 should not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.
v3.26.1
Insider Trading Arrangements
 3 Months Ended
Apr. 05, 2026
shares
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Joel S. Goldberg [Member]  
Trading Arrangements, by Individual  
Name Joel S. Goldberg
Title Senior Vice President, Administration, General Counsel and Secretary
Rule 10b5-1 Arrangement Adopted true
Adoption Date February 10, 2026
Expiration Date 2/1/27
Arrangement Duration 4 days
Aggregate Available 13,313
Prahlad Singh [Member]  
Trading Arrangements, by Individual  
Name Prahlad Singh
Title President and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date February 11, 2026
Expiration Date 2/1/27
Arrangement Duration 4 days
Aggregate Available 47,580
v3.26.1
Revenue (Tables)
 3 Months Ended
Apr. 05, 2026
Disaggregation of Revenue [Line Items]  
Disaggregation of Revenue [Table Text Block]
Disaggregated revenue by primary geographical markets and major goods and service lines are as follows:
Reportable Segments
Three Months Ended
April 5, 2026March 30, 2025
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$185,551 $130,441 $315,992 $184,279 $120,350 $304,629 
Europe91,695 131,351 223,046 76,022 105,770 181,792 
Asia84,599 87,481 172,080 80,094 98,247 178,341 
$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 
Major goods/service lines
Life Sciences Solutions$299,996 $— $299,996 $286,453 $— $286,453 
Software61,849 — 61,849 53,942 — 53,942 
Immunodiagnostics— 201,831 201,831 — 197,562 197,562 
Reproductive Health— 147,442 147,442 — 126,805 126,805 
$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 
v3.26.1
Restructuring and Related Activities (Tables)
 3 Months Ended
Apr. 05, 2026
Restructuring Cost and Reserve [Line Items]  
Restructuring and Other Costs By Segment [Table Text Block]
Restructuring and other costs, which are included in the selling, general and administrative expenses in the consolidated statements of operations, by segment were as follows:
 
Three Months Ended
April 5,
2026		March 30,
2025
 (In thousands)
Life Sciences$3,229 $2,528 
Diagnostics7,554 135 
Corporate(108)576 
$10,675 $3,239 
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]
The following table summarizes the changes in the Company’s accrued restructuring balance for the first quarter of fiscal year 2026. Other amounts reported as restructuring and other costs during the three months ended April 5, 2026 in the accompanying statement of income have been summarized in the notes to the table. Remaining obligations related to these accounts are expected to be paid over the next 12 months and are included in accrued expenses and other current liabilities in the consolidated balance sheets.
(In thousands)
Balance at December 28, 2025$17,793 
Net restructuring charges incurred in 2026 (a)
7,746 
Payments(11,555)
Balance at April 5, 2026$13,984 
(a) Excludes $2.9 million of charges, principally $1.2 million of lease abandonment charges and $0.4 million of acceleration of depreciation of fixed assets and other charges in the Diagnostics segment and $1.3 million of lease abandonment charges in the Life Sciences segment.
v3.26.1
Interest and Other Expense (Income), Net (Tables)
 3 Months Ended
Apr. 05, 2026
Other Income and Expenses [Abstract]  
Interest and Other Expense (Income), Net
Interest and other expense, net, consisted of the following:
 Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Interest income$(6,304)$(10,081)
Interest expense24,718 22,964 
Change in fair value of investments4,204 (3,073)
Other components of net periodic pension (credit) cost(251)6,787 
Foreign exchange losses and other expense, net3,527 3,251 
Total interest and other expense, net$25,894 $19,848 
v3.26.1
Inventories, Net (Tables)
 3 Months Ended
Apr. 05, 2026
Inventory Disclosure [Abstract]  
Schedule of Net Inventories
Inventories, net consisted of the following:
April 5,
2026		December 28,
2025
 (In thousands)
Raw materials$169,780 $173,033 
Work in progress71,466 68,983 
Finished goods146,259 137,481 
Total inventories, net$387,505 $379,497 
v3.26.1
Debt (Tables)
 3 Months Ended
Apr. 05, 2026
Debt Disclosure [Abstract]  
Schedule of Debt
The Company’s debt consisted of the following:

April 5, 2026
Outstanding Principal
Unamortized Debt Discount
Unamortized Debt Issuance Costs
Net Carrying Amount
(In thousands)
Long-Term Debt:
Senior Unsecured Revolving Credit Facility$— $— $(2,677)$(2,677)
1.900% Senior Unsecured Notes due in 2028
500,000 (135)(1,634)498,231 
3.3% Senior Unsecured Notes due in 2029
850,000 (1,101)(3,048)845,851 
2.55% Senior Unsecured Notes due in March 2031400,000 (71)(1,871)398,058 
2.250% Senior Unsecured Notes due in September 2031
500,000 (883)(2,537)496,580 
3.625% Senior Unsecured Notes due in 2051
400,000 (3)(3,968)396,029 
   Total Long-Term Debt2,650,000 (2,193)(15,735)2,632,072 
Current Portion of Long-term Debt:
€500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (“2026 Notes”)
576,150 (174)(145)575,831 
   Total$3,226,150 $(2,367)$(15,880)$3,207,903 
On January 7, 2025, the Company entered into a senior unsecured revolving credit facility with a five-year term and a borrowing capacity of $1.5 billion available through January 7, 2030. Borrowings will bear interest, payable quarterly or, if earlier, at the end of any interest period, at the Company’s option at either (a) the base rate (as described in the credit agreement), or (b) the Term Secured Overnight Financing Rate (“Term SOFR”) (as described in the credit agreement), in each case plus a percentage spread based on the credit rating of the Company’s debt. The base rate is the highest of (a) the Federal Funds Rate (as defined in the credit agreement) plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate”, and (c) Term SOFR plus 1.00%. The credit agreement for the new facility contains customary affirmative, negative and financial covenants and events of default. The financial covenants include a debt-to-capitalization ratio that remains applicable for so long as the Company’s debt is rated as investment grade. In the event that the Company’s debt is not rated as investment grade, the debt-to-capitalization ratio covenant is replaced with leverage ratio and interest coverage ratio covenants.
v3.26.1
Earnings Per Share (Tables)
 3 Months Ended
Apr. 05, 2026
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations The following table reconciles the number of shares utilized in the earnings per share calculations:
 Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Number of common shares—basic111,852 120,137 
Effect of dilutive securities:
Stock options10 42 
Restricted stock awards14 54 
Number of common shares—diluted111,876 120,233 
Number of potentially dilutive securities excluded from calculation due to antidilutive impact1,455 1,134 
v3.26.1
Industry Segment Information (Tables)
 3 Months Ended
Apr. 05, 2026
Segment Reporting [Abstract]  
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations
Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below:  
April 5, 2026March 30, 2025
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$361,845 $349,273 $711,118 $340,395 $324,367 $664,762 
Segment cost of revenue131,574 156,753 119,321 135,190 
Segment selling, general and administrative expenses94,668 90,192 87,094 89,891 
Segment research and development expenses31,624 26,206 28,269 25,271 
Segment operating income$103,979 $76,122 180,101 $105,711 $74,015 179,726 
Corporate expenses(12,247)(9,815)
Amortization of intangible assets(85,081)(82,700)
Purchase accounting adjustments(141)177 
Acquisition and divestiture-related costs(282)(2,541)
Disposition of businesses and assets, net5,074 — 
Transformation costs(794)— 
Significant litigation matters and settlements(69)(10,586)
Significant environmental matters— 1,208 
Restructuring and other(10,675)(3,239)
Interest and other expense, net(25,894)(19,848)
Income from continuing operations before income taxes$49,992 $52,382 
Schedule of Depreciation [Table Text Block]
Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Life Sciences$9,905 $7,185 
Diagnostics9,560 6,846 
Corporate510 691 
Total depreciation expense$19,975 $14,722 
v3.26.1
Stockholders' Equity (Tables)
 3 Months Ended
Apr. 05, 2026
Stockholders' Equity Note [Abstract]  
Components of Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss consisted of the following:
April 5,
2026		December 28,
2025
 (In thousands)
Foreign currency translation adjustments, net of income taxes$(253,554)$(221,062)
Unrecognized prior service costs, net of income taxes— (798)
Unrealized net losses on marketable securities, net of income taxes(2)(275)
Accumulated other comprehensive loss$(253,556)$(222,135)
v3.26.1
Goodwill and Intangible Assets, Net (Tables)
 3 Months Ended
Apr. 05, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Changes in the Carrying Amount of Goodwill
The changes in the carrying amount of goodwill for the three months ended April 5, 2026 were as follows:
Life SciencesDiagnosticsConsolidated
 (In thousands)
Balance at December 28, 2025$4,744,962 $1,868,531 $6,613,493 
Foreign currency translation(24,952)(9,826)(34,778)
Acquisitions32,035 — 32,035 
Balance at April 5, 2026$4,752,045 $1,858,705 $6,610,750 
Identifiable Intangible Asset Balances
Identifiable intangible asset balances by category were as follows:
April 5,
2026		December 28,
2025
 (In thousands)
Patents$27,592 $27,592 
Less: Accumulated amortization(26,579)(26,524)
Net patents1,013 1,068 
Trade names and trademarks148,996 150,103 
Less: Accumulated amortization(103,298)(102,234)
Net trade names and trademarks45,698 47,869 
Licenses27,550 27,561 
Less: Accumulated amortization(20,214)(19,849)
Net licenses7,336 7,712 
Core technology1,641,071 1,624,925 
Less: Accumulated amortization(945,967)(921,325)
Net core technology695,104 703,600 
Customer relationships2,886,388 2,870,384 
Less: Accumulated amortization(1,329,005)(1,283,630)
Net customer relationships1,557,383 1,586,754 
Total$2,306,534 $2,347,003 
v3.26.1
Fair Value Measurements (Tables)
 3 Months Ended
Apr. 05, 2026
Fair Value Disclosures [Abstract]  
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis
The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of April 5, 2026 and December 28, 2025 classified in one of the three classifications described above:
 Fair Value Measurements at April 5, 2026 Using:
 Total Carrying Value at April 5, 2026Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$22,865 $22,865 $— $— 
Foreign exchange derivative assets585 — 585 — 
Foreign exchange derivative liabilities(381)— (381)— 
Contingent consideration asset14,890 — — 14,890 
Contingent consideration liabilities(25,011)— — (25,011)
 
 Fair Value Measurements at December 28, 2025 Using:
 Total Carrying Value at December 28, 2025Quoted Prices in
Active Markets
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable 
Inputs
(Level 3)
 (In thousands)
Marketable securities - available for sale$27,956 $27,956 $— $— 
Foreign exchange derivative assets1,832 — 1,832 — 
Foreign exchange derivative liabilities(1,487)— (1,487)— 
Contingent consideration asset14,890 — — 14,890 
Contingent consideration liabilities(17,869)— — (17,869)
Reconciliation of Beginning and Ending Level 3 Net Liabilities
A reconciliation of the beginning and ending Level 3 contingent consideration liabilities is as follows:
 Three Months Ended
 April 5,
2026		March 30,
2025
 (In thousands)
Balance at beginning of period$(17,869)$(21,753)
Additions(8,000)— 
Amounts paid and foreign currency translation759 1,388 
Change in fair value (included within selling, general and administrative expenses)99 625 
Balance at end of period$(25,011)$(19,740)
v3.26.1
Basis of Presentation (Basis of Presentation) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Dec. 28, 2025
Basis of Presentation [Line Items]      
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ (7,627) $ 16,122  
Operating Lease, Right-of-Use Asset $ 163,254   $ 165,439
v3.26.1
Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Dec. 28, 2025
Disaggregation of Revenue [Line Items]      
Segment revenue $ 711,118 $ 664,762  
Unbilled Receivables 106,700   $ 105,600
Unbilled Receivables, Current 74,400   72,400
Unbilled Receivables, noncurrent 32,300   33,200
Deferred Revenue 238,500   224,800
Deferred Revenue, Current 171,700   159,300
Deferred Revenue, Noncurrent 66,800   65,500
Customer Deposits Received in Advance of Transfer of Control $ 20,300   $ 19,300
Remaining Performance Obligations Transaction price allocated to the remaining performance obligationsThe Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.    
Contract with Customer, Asset and Liability [Abstract]      
Contract with Customer, Asset, Net, Current - Not Material The Company had no material contract assets as of April 5, 2026 and December 28, 2025.    
Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue $ 315,992 304,629  
Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 223,046 181,792  
Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 172,080 178,341  
Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 349,273 324,367  
Diagnostics [Member] | Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 130,441 120,350  
Diagnostics [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 131,351 105,770  
Diagnostics [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 87,481 98,247  
Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 361,845 340,395  
Life Sciences [Member] | Americas [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 185,551 184,279  
Life Sciences [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 91,695 76,022  
Life Sciences [Member] | Asia [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 84,599 80,094  
Life Sciences Solutions [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 299,996 286,453  
Life Sciences Solutions [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0  
Life Sciences Solutions [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 299,996 286,453  
Software [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 61,849 53,942  
Software [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0  
Software [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 61,849 53,942  
Reproductive health [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 147,442 126,805  
Reproductive health [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 147,442 126,805  
Reproductive health [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 0 0  
Applied genomics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue   664,762  
Immunodiagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 201,831 197,562  
Immunodiagnostics [Member] | Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue 201,831 197,562  
Immunodiagnostics [Member] | Life Sciences [Member]      
Disaggregation of Revenue [Line Items]      
Segment revenue $ 0 $ 0  
v3.26.1
Business Combinations (Narrative) (Details)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
USD ($)
employees
Dec. 28, 2025
USD ($)
Mar. 30, 2025
USD ($)
Dec. 29, 2024
USD ($)
Business Combination [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 25,011 $ 17,869 $ 19,740 $ 21,753
Goodwill 6,610,750 6,613,493    
Goodwill, Acquisition $ 32,035      
Advanced Chemistry Development Inc. [Member]        
Business Combination [Line Items]        
Business Combination, Number Of Employees Acquired | employees 200      
Life Sciences [Member]        
Business Combination [Line Items]        
Goodwill $ 4,752,045 4,744,962    
Goodwill, Acquisition $ 32,035      
Life Sciences [Member] | Advanced Chemistry Development Inc. [Member]        
Business Combination [Line Items]        
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 11 years 3 months 18 days      
Goodwill, Acquisition $ 32,000      
Diagnostics [Member]        
Business Combination [Line Items]        
Goodwill 1,858,705 $ 1,868,531    
Goodwill, Acquisition 0      
Customer Relationships [Member] | Life Sciences [Member] | Advanced Chemistry Development Inc. [Member]        
Business Combination [Line Items]        
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived 18,200      
Trademarks and Trade Names [Member] | Life Sciences [Member] | Advanced Chemistry Development Inc. [Member]        
Business Combination [Line Items]        
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived 800      
Backlog [Member] | Life Sciences [Member] | Advanced Chemistry Development Inc. [Member]        
Business Combination [Line Items]        
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived 1,100      
Developed Technology [Member] | Life Sciences [Member] | Advanced Chemistry Development Inc. [Member]        
Business Combination [Line Items]        
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived 30,100      
United States of America, Dollars | Advanced Chemistry Development Inc. [Member]        
Business Combination [Line Items]        
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments 72,000      
Business Combination, Contingent Consideration, Liability $ 8,000      
v3.26.1
Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) - USD ($)
$ in Thousands
Apr. 05, 2026
Dec. 28, 2025
Business Combination [Line Items]    
Goodwill $ 6,610,750 $ 6,613,493
v3.26.1
Restructuring and Related Activities (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Restructuring Cost and Reserve [Line Items]    
Restructuring and Other Costs (Income) $ 10,675 $ 3,239
Other Charges Included in Restructuring and Other Costs $ 2,900  
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent 2.00%  
Restructuring Reserve [Roll Forward]    
Restructuring Reserve, Beginning Balance $ 17,793  
Net restructuring charges incurred 7,746  
Payments for Restructuring (11,555)  
Restructuring Reserve, Ending Balance 13,984  
Life Sciences [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring and Other Costs (Income) 3,229 2,528
Lease Abandonment Charges Included In Restructuring and Other Costs 1,300  
Diagnostics [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring and Other Costs (Income) 7,554 135
Lease Abandonment Charges Included In Restructuring and Other Costs 1,200  
Acceleration of depreciation of fixed assets and other charges 400  
Corporate Expenses [Member]    
Restructuring Cost and Reserve [Line Items]    
Restructuring and Other Costs (Income) $ (108) $ 576
v3.26.1
Interest and Other Expense (Income), Net (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Other Income and Expenses [Abstract]    
Interest income $ (6,304) $ (10,081)
Interest Expense 24,718 22,964
Change in fair value of financial securities 4,204 (3,073)
Other components of net periodic pension (credit) cost (251) 6,787
Foreign exchange losses and other expense (income), net 3,527 3,251
Total interest and other expense, net $ 25,894 $ 19,848
v3.26.1
Inventories, Net (Details) - USD ($)
$ in Thousands
Apr. 05, 2026
Dec. 28, 2025
Inventory Disclosure [Abstract]    
Raw materials $ 169,780 $ 173,033
Work in progress 71,466 68,983
Finished goods 146,259 137,481
Total inventories, net $ 387,505 $ 379,497
v3.26.1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Income Tax Contingency [Line Items]    
Provision for income taxes $ 9,099 $ 10,713
v3.26.1
Debt (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 07, 2025
Apr. 05, 2026
Dec. 28, 2025
Interest rate terms, senior unsecured revolving credit facility   Borrowings will bear interest, payable quarterly or, if earlier, at the end of any interest period, at the Company’s option at either (a) the base rate (as described in the credit agreement), or (b) the Term Secured Overnight Financing Rate (“Term SOFR”) (as described in the credit agreement), in each case plus a percentage spread based on the credit rating of the Company’s debt. The base rate is the highest of (a) the Federal Funds Rate (as defined in the credit agreement) plus 0.50%, (b) the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its “prime rate”, and (c) Term SOFR plus 1.00%  
Debt Instrument, Unamortized Discount   $ (2,367)  
Unamortized Debt Issuance Expense   (15,880)  
Current portion of long-term debt   575,831 $ 588,828
Debt, Long-term and Short-term, Combined Amount   3,226,150  
Long-term Debt, Gross   2,650,000  
Significant Other Observable Inputs (Level 2) [Member]      
Long-term Debt   (2,632,072)  
Debt, Long-term and Short-term, Combined Amount   3,207,903  
2.55 Percent Senior Unsecured Notes due in 2031 [Member]      
Debt Instrument, Unamortized Discount   (71)  
Unamortized Debt Issuance Expense   (1,871)  
Long-term Debt, Gross   400,000  
2.55 Percent Senior Unsecured Notes due in 2031 [Member] | Significant Other Observable Inputs (Level 2) [Member]      
Long-term Debt   (398,058)  
3.625 Percent Senior Unsecured Notes due in 2051 [Member]      
Debt Instrument, Unamortized Discount   (3)  
Unamortized Debt Issuance Expense   (3,968)  
Long-term Debt, Gross   400,000  
3.625 Percent Senior Unsecured Notes due in 2051 [Member] | Significant Other Observable Inputs (Level 2) [Member]      
Long-term Debt   (396,029)  
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]      
Debt Instrument, Unamortized Discount   (1,101)  
Unamortized Debt Issuance Expense   (3,048)  
Long-term Debt, Gross   850,000  
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member] | Significant Other Observable Inputs (Level 2) [Member]      
Long-term Debt   (845,851)  
1.875 Percent Ten Year Senior Unsecured Notes [Member]      
Debt Instrument, Unamortized Discount   (174)  
Unamortized Debt Issuance Expense   (145)  
Current Portion of Long-Term Debt, Gross   576,150  
1.875 Percent Ten Year Senior Unsecured Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]      
Current portion of long-term debt   575,831  
Line of Credit, Maturing August 24, 2026 [Member]      
Unsecured revolving credit facility, termination date Jan. 07, 2025    
1.900% Senior Unsecured Notes due 2028 [Member]      
Debt Instrument, Unamortized Discount   (135)  
Unamortized Debt Issuance Expense   (1,634)  
Long-term Debt, Gross   500,000  
1.900% Senior Unsecured Notes due 2028 [Member] | Significant Other Observable Inputs (Level 2) [Member]      
Long-term Debt   (498,231)  
2.250% Senior Unsecured Notes due in 2031 [Member]      
Debt Instrument, Unamortized Discount   (883)  
Unamortized Debt Issuance Expense   (2,537)  
Long-term Debt, Gross   500,000  
2.250% Senior Unsecured Notes due in 2031 [Member] | Significant Other Observable Inputs (Level 2) [Member]      
Long-term Debt   (496,580)  
Line of Credit, Maturing January 7, 2030      
Unsecured Revolving Credit Facility, Initiation Date Jan. 07, 2025    
Unsecured revolving credit facility, maturity date Jan. 07, 2030    
Line of Credit Facility, Maximum Borrowing Capacity $ 1,500,000    
Debt Instrument, Unamortized Discount   0  
Long-term Debt   (2,677)  
Unamortized Debt Issuance Expense   (2,677)  
Revolving credit facility outstanding balance   $ 0  
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing January 7, 2030 | Federal Funds Rate [Member]      
Basis spread on variable rate   0.50%  
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing January 7, 2030 | Secured Overnight Financing Rate (SOFR) [Member]      
Basis spread on variable rate   1.00%  
Long-term Debt [Member]      
Debt Instrument, Unamortized Discount   $ (2,193)  
Unamortized Debt Issuance Expense   $ (15,735)  
v3.26.1
Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) - shares
shares in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Earnings Per Share [Abstract]    
Number of common shares-basic 111,852 120,137
Effect of dilutive securities, Stock options 10 42
Effect of dilutive securities, Restricted stock 14 54
Number of common shares-diluted 111,876 120,233
Number of potentially dilutive securities excluded from calculation due to antidilutive impact 1,455 1,134
v3.26.1
Industry Segment Information Industry Segment Information Narrative (Details)
 3 Months Ended
Apr. 05, 2026
segments
Segment Reporting [Line Items]  
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Chief Executive Officer [Member]
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description The primary financial measure by which the CODM evaluates the performance of Company’s segments is adjusted operating income. Adjusted operating income consists of operating income plus amortization of intangible assets, adjustments to operations arising from purchase accounting (primarily adjustments to the fair value of acquired inventory that are subsequently recognized), acquisition and divestiture-related costs, and other costs that are not expected to recur or are of a non-cash nature, primarily including restructuring actions, significant litigation matters and transformation costs. The CODM does not evaluate operating segments using discrete asset information and segment assets are not reported to the CODM. Accordingly, no segment assets have been reported.
Number of Reportable Segments 2
v3.26.1
Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Segment Reporting [Line Items]    
Segment revenue $ 711,118 $ 664,762
Total amortization expense related to finite-lived intangible assets 85,100 82,700
Operating income (loss) from continuing operations 75,886 72,230
Interest and other expense, net 25,894 19,848
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 49,992 52,382
Gain (Loss) on Disposition of Assets 5,074 0
Product [Member]    
Segment Reporting [Line Items]    
Segment revenue 581,458 562,680
Service [Member]    
Segment Reporting [Line Items]    
Segment revenue 129,660 102,082
Diagnostics [Member]    
Segment Reporting [Line Items]    
Segment revenue 349,273 324,367
Segment operating income 76,122 74,015
Life Sciences [Member]    
Segment Reporting [Line Items]    
Segment revenue 361,845 340,395
Segment operating income 103,979 105,711
Reportable Segment Revenue [Member]    
Segment Reporting [Line Items]    
Segment revenue 711,118 664,762
Reportable Segment Revenue [Member] | Diagnostics [Member]    
Segment Reporting [Line Items]    
Segment revenue 349,273 324,367
Reportable Segment Revenue [Member] | Life Sciences [Member]    
Segment Reporting [Line Items]    
Segment revenue 361,845 340,395
Segment Operating Income [Member]    
Segment Reporting [Line Items]    
Segment operating income 180,101 179,726
Segment Operating Income [Member] | Diagnostics [Member]    
Segment Reporting [Line Items]    
Segment Cost of Revenue 156,753 135,190
Segment Selling, general and administrative expenses 90,192 89,891
Segment research and development expenses 26,206 25,271
Segment Operating Income [Member] | Life Sciences [Member]    
Segment Reporting [Line Items]    
Segment Cost of Revenue 131,574 119,321
Segment Selling, general and administrative expenses 94,668 87,094
Segment research and development expenses 31,624 28,269
Reconciling Item (to Reconcile Segment Operating Income to Income from Continuing Operations before Income Taxes) [Member]    
Segment Reporting [Line Items]    
Corporate Expenses (12,247) (9,815)
Total amortization expense related to finite-lived intangible assets (85,081) (82,700)
Purchase accounting adjustments (141) 177
Acquisition and divestiture-related costs (282) (2,541)
Significant litigation matters and settlements (69) (10,586)
Restructuring and other, net (10,675) (3,239)
Significant environmental matters 0 1,208
Transformation costs $ (794) $ 0
v3.26.1
Industry Segment and Geographic Area Information Schedule of Depreciation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Segment Reporting [Line Items]    
Depreciation expense $ 19,975 $ 14,722
Life Sciences [Member]    
Segment Reporting [Line Items]    
Depreciation expense 9,905 7,185
Diagnostics [Member]    
Segment Reporting [Line Items]    
Depreciation expense 9,560 6,846
Corporate (Reconciling Item) [Member]    
Segment Reporting [Line Items]    
Depreciation expense $ 510 $ 691
v3.26.1
Stockholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Oct. 23, 2025
Jul. 05, 2026
Apr. 05, 2026
Dec. 28, 2025
Sep. 28, 2025
Jun. 29, 2025
Mar. 30, 2025
Aug. 14, 2026
May 08, 2026
Schedule of Shareholders' Equity [Line Items]                  
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans     51,115            
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans     $ 5.0            
Cash dividends (per share)     $ 0.07 $ 0.07 $ 0.07 $ 0.07 $ 0.07    
Unrealized Foreign Exchange Losses (Gains) on Intercompany Debt in AOCI     $ 39.9       $ (58.1)    
Income taxes related to foreign currency translation adjustments recognized in AOCI     (12.9)       $ 4.2    
O2026Q1Dividends [Member]                  
Schedule of Shareholders' Equity [Line Items]                  
Dividends Payable, Amount     $ 7.8            
Dividends Payable, Date Declared     Jan. 26, 2026            
Repurchase Program, 10/23/2025 [Member]                  
Schedule of Shareholders' Equity [Line Items]                  
Stock Repurchase Program, Authorized Amount $ 1,000.0                
Stock Repurchase Program, Remaining Authorized Repurchase Amount     $ 800.5            
Number of common stock repurchased in open market     784,142            
Aggregate Cost of Repurchased Common Shares Under Repurchase Program     $ 79.0            
Share Repurchase Program, Start Date Oct. 23, 2025                
Share Repurchase Program, Expiration Date     Oct. 22, 2027            
Subsequent Event [Member] | O2026Q1Dividends [Member]                  
Schedule of Shareholders' Equity [Line Items]                  
Dividends Payable, Date to be Paid, Year and Month                 2026-05
Subsequent Event [Member] | O2026Q2Dividends [Member]                  
Schedule of Shareholders' Equity [Line Items]                  
Cash dividends (per share)   $ 0.07              
Dividends Payable, Date Declared   Apr. 30, 2026              
Dividends Payable, Date to be Paid, Year and Month               2026-08  
Subsequent Event [Member] | Repurchase Program, 10/23/2025 [Member]                  
Schedule of Shareholders' Equity [Line Items]                  
Number of common stock repurchased in open market   93,303              
Aggregate Cost of Repurchased Common Shares Under Repurchase Program   $ 7.8              
v3.26.1
Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($)
$ in Thousands
Apr. 05, 2026
Dec. 28, 2025
Stockholders' Equity Note [Abstract]    
Foreign currency translation adjustments, net of income taxes $ (253,554) $ (221,062)
Unrecognized losses and prior service costs, net of income taxes 0 (798)
Unrealized net losses on securities, net of income taxes (2) (275)
Accumulated other comprehensive loss $ (253,556) $ (222,135)
v3.26.1
Goodwill and Intangible Assets, Net (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Dec. 28, 2025
Goodwill and Intangible Assets Net [Line Items]      
Goodwill $ 6,610,750   $ 6,613,493
Total amortization expense related to finite-lived intangible assets 85,100 $ 82,700  
Future Amortization Expense, Remainder of Fiscal Year 254,500    
Future Amortization Expense, Year One 312,700    
Future Amortization Expense, Year Two 286,800    
Future Amortization Expense, Year Three 256,700    
Future Amortization Expense, Year Four 227,900    
Intangible Asset, Finite-Lived, after Accumulated Amortization 2,306,534   2,347,003
Intangible assets, net 2,306,534   2,347,003
Patents [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Gross amortizable intangible assets 27,592   27,592
Less: Accumulated amortization 26,579   26,524
Intangible Asset, Finite-Lived, after Accumulated Amortization 1,013   1,068
Trade Names And Trademarks [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Gross amortizable intangible assets 148,996   150,103
Less: Accumulated amortization 103,298   102,234
Intangible Asset, Finite-Lived, after Accumulated Amortization 45,698   47,869
Licensing Agreements [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Gross amortizable intangible assets 27,550   27,561
Less: Accumulated amortization 20,214   19,849
Intangible Asset, Finite-Lived, after Accumulated Amortization 7,336   7,712
Core Technology [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Gross amortizable intangible assets 1,641,071   1,624,925
Less: Accumulated amortization 945,967   921,325
Intangible Asset, Finite-Lived, after Accumulated Amortization 695,104   703,600
Customer Relationships [Member]      
Goodwill and Intangible Assets Net [Line Items]      
Gross amortizable intangible assets 2,886,388   2,870,384
Less: Accumulated amortization 1,329,005   1,283,630
Intangible Asset, Finite-Lived, after Accumulated Amortization $ 1,557,383   $ 1,586,754
v3.26.1
Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
USD ($)
Changes in the carrying amount of goodwill  
Balance at beginning of period $ 6,613,493
Foreign currency translation (34,778)
Goodwill, Acquisition 32,035
Balance at end of period 6,610,750
Life Sciences [Member]  
Changes in the carrying amount of goodwill  
Balance at beginning of period 4,744,962
Foreign currency translation (24,952)
Goodwill, Acquisition 32,035
Balance at end of period 4,752,045
Diagnostics [Member]  
Changes in the carrying amount of goodwill  
Balance at beginning of period 1,868,531
Foreign currency translation (9,826)
Goodwill, Acquisition 0
Balance at end of period $ 1,858,705
v3.26.1
Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) - USD ($)
$ in Thousands
Apr. 05, 2026
Dec. 28, 2025
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Net amortizable intangible assets $ 2,306,534 $ 2,347,003
Intangible assets, net 2,306,534 2,347,003
Patents [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 27,592 27,592
Less: Accumulated amortization (26,579) (26,524)
Net amortizable intangible assets 1,013 1,068
Trade Names And Trademarks [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 148,996 150,103
Less: Accumulated amortization (103,298) (102,234)
Net amortizable intangible assets 45,698 47,869
Licensing Agreements [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 27,550 27,561
Less: Accumulated amortization (20,214) (19,849)
Net amortizable intangible assets 7,336 7,712
Core Technology [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 1,641,071 1,624,925
Less: Accumulated amortization (945,967) (921,325)
Net amortizable intangible assets 695,104 703,600
Customer Relationships [Member]    
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]    
Gross amortizable intangible assets 2,886,388 2,870,384
Less: Accumulated amortization (1,329,005) (1,283,630)
Net amortizable intangible assets $ 1,557,383 $ 1,586,754
v3.26.1
Derivatives And Hedging Activities (Details)
€ in Millions, $ in Millions
 3 Months Ended
Apr. 05, 2026
USD ($)
Apr. 05, 2026
EUR (€)
Mar. 30, 2025
USD ($)
Dec. 28, 2025
USD ($)
Derivative [Line Items]        
Company's business conducted outside United States 60.00% 60.00%    
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net $ 0.0      
European And Asian Currencies [Member]        
Derivative [Line Items]        
Maximum maturity period for foreign exchange contracts, in months 12 months 12 months    
Duration Of Foreign Currency Derivatives 30 days 30 days    
Fair Value Hedging [Member]        
Derivative [Line Items]        
Derivative, Notional Amount $ 459.8     $ 598.4
Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]        
Derivative [Line Items]        
Unrealized Gain (Loss) on Net Investment Hedge in AOCI $ 13.3   $ (19.2)  
Euro Member Countries, Euro | Net Investment Hedging [Member] | 1.875 Percent Ten Year Senior Unsecured Notes [Member]        
Derivative [Line Items]        
Notional Amount of Nonderivative Instruments | €   € 498.6    
v3.26.1
Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Dec. 28, 2025
Dec. 29, 2024
Mar. 13, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 25,011 $ 19,740 $ 17,869 $ 21,753  
Unamortized Debt Issuance Expense 15,880        
Debt Instrument, Unamortized Discount (2,367)        
Payment for Contingent Consideration Liability, Financing Activities 0 $ 1,817      
Analytical, Food and Enterprise Services businesses [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Disposal Group, Consideration, Contingent on Exit Valuation         $ 150,000
2.55 Percent Senior Unsecured Notes due in 2031 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Unamortized Debt Issuance Expense 1,871        
Debt Instrument, Unamortized Discount (71)        
3.625 Percent Senior Unsecured Notes due in 2051 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Unamortized Debt Issuance Expense 3,968        
Debt Instrument, Unamortized Discount (3)        
1.875 Percent Ten Year Senior Unsecured Notes [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Unamortized Debt Issuance Expense 145        
Debt Instrument, Unamortized Discount (174)        
3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Unamortized Debt Issuance Expense 3,048        
Debt Instrument, Unamortized Discount (1,101)        
Quoted Prices In Active Markets (Level 1) [Member] | Fair Value, Recurring [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0   0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0   0    
Significant Other Observable Inputs (Level 2) [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt 2,632,072        
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Recurring [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0   0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0   0    
Significant Other Observable Inputs (Level 2) [Member] | 2.55 Percent Senior Unsecured Notes due in 2031 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt 398,058        
Significant Other Observable Inputs (Level 2) [Member] | 3.625 Percent Senior Unsecured Notes due in 2051 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt 396,029        
Significant Other Observable Inputs (Level 2) [Member] | 3.3 Percent Ten Year Senior Unsecured Notes due in Sept 2029 [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt 845,851        
Significant Other Observable Inputs (Level 2) [Member] | Senior Unsecured Notes [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term Debt 3,210,600   3,222,900    
Unsecured senior notes, fair value 2,950,600   2,963,700    
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Recurring [Member]          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 25,011   17,869    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $ 14,890   $ 14,890    
v3.26.1
Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) - USD ($)
$ in Thousands
Apr. 05, 2026
Dec. 28, 2025
Mar. 30, 2025
Dec. 29, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 25,011 $ 17,869 $ 19,740 $ 21,753
Fair Value, Recurring [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 22,865 27,956    
Foreign exchange derivative assets, net (585) (1,832)    
Foreign exchange derivative liabilities, net (381) (1,487)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890 14,890    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 25,011 17,869    
Fair Value, Recurring [Member] | Quoted Prices In Active Markets (Level 1) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 22,865 27,956    
Foreign exchange derivative assets, net 0 0    
Foreign exchange derivative liabilities, net 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0    
Fair Value, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 0 0    
Foreign exchange derivative assets, net (585) (1,832)    
Foreign exchange derivative liabilities, net (381) (1,487)    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0 0    
Fair Value, Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Marketable securities 0 0    
Foreign exchange derivative assets, net 0 0    
Foreign exchange derivative liabilities, net 0 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value 14,890 14,890    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 25,011 $ 17,869    
v3.26.1
Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Apr. 05, 2026
Mar. 30, 2025
Fair Value Disclosures [Abstract]    
Balance beginning of period $ (17,869) $ (21,753)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 8,000 0
Payments 759 1,388
Change in fair value (included within selling, general and administrative expenses) 99 625
Balance end of period $ (25,011) $ (19,740)
v3.26.1
Contingencies (Details)
$ in Millions
 3 Months Ended
Apr. 05, 2026
USD ($)
years
Dec. 28, 2025
USD ($)
Commitments and Contingencies Disclosure [Abstract]    
Management's estimate of total cost of ultimate disposition | $ $ 10.7 $ 10.8
Number of years over which estimated environmental cost will be paid | years 10  
v3.26.1
Subsequent Events (Details)
$ in Millions
Mar. 13, 2023
USD ($)
Analytical, Food and Enterprise Services businesses [Member]  
Subsequent Event [Line Items]  
Disposal Group, Consideration, Contingent on Exit Valuation $ 150.0